Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 102.50
Bid: 100.00
Ask: 105.00
Change: 7.50 (7.89%)
Spread: 5.00 (5.00%)
Open: 93.50
High: 102.50
Low: 93.50
Prev. Close: 95.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

Thu, 13th Oct 2022 21:17

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Bidstack Group PLC - London-based in-game advertising platform - Appoints Camila Franklin as chief operating officer. She is replacing Lisa Hau who will move on to be the company's chief strategy officer. Franklin was previously COO at the gaming monetisation platform AdColony Inc.

----------

Hamak Gold Ltd - British Virgin Islands-based gold exploration firm focused on Liberia - Signs a contract with Cestos Drilling Liberia for an initial drilling programme to identify the depth and width extensions of significant gold mineralization. "We will shortly commence a drilling programme to test the width and depth extensions of the significant gold mineralization identified by soil and channel sampling over the Ziatoyah outcrop in our Nimba licence. We are pleased to be working with Cestos who have agreed to accept equity for the majority of their drilling services, showing their confidence in our programme and helping to conserve cash for the company in these challenging equity markets," Executive Director Karl Smithson comments.

----------

Amigo Holdings PLC - Bournemouth, England-based guarantor loan provider - Gets approval from the Financial Conduct Authority to return to lending with immediate effect. Notes that this is under "certain agreed conditions." Under the terms, it will undertake further customer outcomes testing, led by a third party, during the initial two-month pilot lending phase and a required period for assessment. If the FCA is satisfied with the outcome of this pilot phase, it will still be limited to a maximum of GBP35 million cumulative net originations until a further minimum GBP15 million scheme contribution from the proposed capital raise is paid into the scheme fund, it says.

----------

Arbuthnot Banking Group PLC - London-based bank - Notes its subsidiary, Arbuthnot Latham & Co Ltd, completed the sale of its long leasehold West End office property, 20 King Street, following the satisfaction of conditions.

----------

Fintel PLC - Huddersfield, England-based technology and support for retail financial services sector - Expands its strategic distribution partnership with Schroders PLC. Says Schroders will join Fintel's Risk Controlled investment solution. "Schroders and Fintel have worked closely together for a number of years and I am delighted that they have chosen to further strengthen this relationship by joining our Risk Controlled range. Fintel exists to help the market operate more effectively and with the continued success of the Managed Distribution and Risk Controlled we continue to deliver the technology and insight-led solutions the industry needs to ensure better consumer outcomes," Joint Chief Executive Matt Timmins comments.

----------

Minoan Group PLC - Surrey-based Greek hotel investor - Appoints Marco Nijhof to its board effective immediately. Says he is a board-level executive within the international luxury hotel and retail hospitality industry. "The appointment of Marco today is one of the final keys to reaching the commercialisation stages of the project. His experience in developing, commercialising and operating world-class tourism and other businesses will be crucial in the coming months as we near crystallisation of the project with the attendant increase in shareholder value," Chair George Mergos comments.

----------

Silverwood Brands PLC - London-based investing company targeting food, organic food, wellness, lifestyle and leisure sectors - Raises gross proceeds of GBP2.0 million through a subscription for new ordinary shares at an issue price of 40 pence per share. Records total income of GBP831,415 in the year to August 31. Net loss total GBP299,103.

----------

Artemis Resources Ltd - Perth-based miner with gold, copper and cobalt projects in Australia - Says the Greater Carlow project is a "high-grade gold copper-cobalt project primed for further growth". Says its resource compares very favourably to other gold mining projects on a grade equivalent basis. "What we have now established at the Greater Carlow project is a robust, credible, high-grade multi-metal resource from which our exploration team can now seek to continue to grow via drilling. The next phase at Greater Carlow is to drill and add more high-grade tonnes to the open pit and underground resources, including the high-grade Keel Zone which is not included in this resource statement," Executive Director Alastair Clayton comments.

----------

Cobra Resources PLC - Wudinna gold project in South Australia - Starts reverse circulation drilling at the Clarke prospect of its Wudinna gold project. This drilling will inform an updated gold mineral resource estimate and a maiden rare earth mineral resource estimate, it says.

----------

Firing Strategic Minerals PLC - operator of Atex dual lithium-tantalum project in Ivory Coast - Drills a total of 19 holes and completes 3,039 meters of drilling. It intersects pegmatite in all 19 drill holes. "I am pleased to provide our next update regarding our phase 1 core drilling programme, which has been completed successfully ... Lithium mineralisation was visually observed in eighteen out of the 19 holes, and we are now eagerly awaiting the assay results, the first of which should arrive during the fourth quarter of 2022," Chief Executive Yuval Cohen says.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Proposes a private placement to raise around EUR8 million through an accelerated book building. Plans to use the net proceeds of the placing would be used for the acceleration of the bexmarilimab clinical development programme and manufacturing. Total cash and cash equivalents held by the company as of June 30 amounted to EUR9.9 million.

----------

CleanTech Lithium PLC - Jersey-based lithium exploration and development company focused on Chile - Starts direct lithium extraction process work at its sustainable lithium projects in Chile. "We are delighted to move forward our process test-work with SunResin on multiple fronts including trials on brine from the sub-surface aquifers of our Laguna Verde and Francisco Basin projects, ordering of a DLE demo unit which will arrive in Chile this month and receiving a proposal for the DLE unit for a pilot plant that will produce battery grade lithium carbonate and lithium hydroxide for customer testing and verification," Chief Executive Aldo Boitano comments.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Dec 2022 21:42

TRADING UPDATES: Renalytix hails trial results; Kingswood buys JFP

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Nov 2022 19:49

TRADING UPDATES: Joules nomad resigns; Pharma C loss narrows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
31 Oct 2022 19:58

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
14 Oct 2022 11:14

Faron Pharmaceuticals shares down as raises EUR8.4 million in placing

(Alliance News) - Faron Pharmaceuticals Ltd shares declined on Friday, after it said it has raised EUR8.4 million from a share placing.

Read more
25 Aug 2022 12:10

REPEAT: Faron Pharma half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
25 Aug 2022 11:43

Faron Pharmaceuticals half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
18 Aug 2022 16:02

UK earnings, trading statements calendar - next 7 days

Friday 19 August 
Apax Global Alpha LtdHalf Year Results
Kingspan Group PLCHalf Year Results
Newcrest Mining LtdFull Year Results
Monday 22 August 
Smoove PLCFull Year Results
Tuesday 23 August 
Aferian PLCHalf Year Results
John Wood Group PLCHalf Year Results
Wednesday 24 August 
Costain Group PLCHalf Year Results
Lookers PLCHalf Year Results
Standard Chartered PLCHalf Year Results
Thursday 25 August 
Amigo Holdings PLCQ1 Results
Anglo Pacific Group PLCHalf Year Results
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
Grafton Group PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Morses Club PLCFull Year Results
South32 LtdFull Year Results
  
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
30 Jun 2022 15:59

UK shareholder meetings calendar - next 7 days

Friday 1 July 
All Star Minerals PLCGM re name change to Marula Mining
Monday 4 July 
Active Energy Group PLCAGM
Clean Invest Africa PLCAGM
Securities Trust of Scotland PLCAGM
Tuesday 5 July 
Immediate Acquisition PLCAGM
Marks & Spencer Group PLCAGM
Open Orphan PLCAGM
Saga PLCAGM
Smartspace Software PLCAGM
Young & Co's Brewery PLCAGM
Wednesday 6 July 
Assura PLCAGM
ContourGlobal PLCGM re acquisition by KKR
GSK PLCGM re Consumer Healthcare demerger, Haleon listing
Mining Minerals & Metals PLCAGM
PCF Group PLCGM re director allotment authority
Puma Alpha VCT PLCAGM
Shires Income PLCAGM
Sirius Real Estate LtdAGM
Strategic Minerals PLCAGM
Worldwide Healthcare Trust PLCAGM
Thursday 7 July 
C&C Group PLCAGM
Distil PLCAGM
Emmerson PLCAGM
Faron Pharmaceuticals LtdGM re issuance of shares
FD Technologies PLCAGM
Great Portland Estates PLCAGM
Greencare Capital PLCAGM
J Sainsbury PLCAGM
JPMorgan European Growth & Income PLCAGM
Land Securities Group PLCAGM
Likewise Group PLCGM re approval of waiver by takeover/merger panel
N Brown Group PLCAGM
Octopus Apollo VCT PLCAGM
Peel Hunt LtdAGM
Pets At Home Group PLCAGM
Puma VCT 13 PLCAGM
Severn Trent PLCAGM
TomCo Energy PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
28 Jun 2022 18:03

IN BRIEF: Faron raises EUR5 million for bexmarilimab development

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset.

Read more
15 Jun 2022 19:24

IN BRIEF: Faron Pharma reveals topline results from MATINS trial

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.

Read more
8 Jun 2022 16:54

IN BRIEF: Faron Pharma doses first patient in bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains.

Read more
16 May 2022 17:35

IN BRIEF: US and Finland approve Faron's bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.

Read more
12 May 2022 19:45

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Apr 2022 19:30

IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.